PMA device
TheraSphere
Boston Scientific Corporation · Microspheres Radionuclide (NAW, Class III) · First FDA decision Mar 17, 2021, newest Aug 21, 2026Liver disease and liver cancer
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
7
PMA pathway
Device trials
40
Naming "TheraSphere"
MAUDE reports
486
Brand "TheraSphere", since 2015
PubMed studies
100
Mentioning "TheraSphere"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing TheraSphere
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 7 decisions filed under this name.
- TheraSpherePMA supplement
P200029-S014 · Decided Aug 21, 2026 · 30 days after receipt · Normal 180 Day Track No User Fee
Device type: Microspheres radionuclide (NAW) · Radiology & Imaging
- TheraSpherePMA supplement
P200029-S012 · Decided Apr 10, 2026 · 30 days after receipt · Normal 180 Day Track No User Fee
Device type: Microspheres radionuclide (NAW) · Radiology & Imaging
- TheraSpherePMA supplement
P200029-S011 · Decided Feb 10, 2026 · 508 days after receipt · Panel Track
Device type: Microspheres radionuclide (NAW) · Radiology & Imaging
3 more FDA decisions with a free account
Older decisions: P200029
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "TheraSphere", any status and sponsor, newest update first.
- A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning.Not yet recruiting
Boston Scientific CorporationPublic (BSX)
NCT07669727 · 140 participants (planned) · Start Jan 2027 · Primary completion May 2028
Device: TheraSphere · For: Hepatocellular Carcinoma (HCC)
- TheraSphere With Durvalumab and Tremelimumab for HCCActive, not recruiting
Boston Scientific CorporationPublic (BSX)
NCT05063565 · 100 participants (planned) · Start Nov 3, 2023 · Primary completion Jun 2027
Device: TheraSphere Y-90 glass microsphere therapy · For: Hepatocellular Carcinoma
Sites: San Diego, California; San Francisco, California; Washington D.C., District of Columbia · 35 sites in all
- Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) DeviceActive, not recruiting
Boston Scientific CorporationPublic (BSX)
NCT06192758 · 36 participants (planned) · Start Apr 15, 2024 · Primary completion Jan 2028
Device: TheraSphere PCa · For: Prostate; Cancer
Sites: Chicago, Illinois
37 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "TheraSphere", and for the whole product code for context.
This brand
486 reports: 20 malfunction, 318 injury, 110 death
Whole product code NAW
540 reports: 29 malfunction, 349 injury, 126 death
Newest reports for this brand
- TheraSphere?Malfunction
2124215-2026-55767 · Received Oct 20, 2026 · Event dated Sep 24, 2026
Device type: Microspheres Radionuclide (NAW)
Device problem as coded: Improper Flow or Infusion; Infusion or Flow Problem; Radiation Underexposure
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- TheraSphere Administration SetMalfunction
BIOCOMPATIBLES U.K. LIMITED, A BTG Company
51085851 · Received Oct 13, 2026 · Event dated Sep 24, 2026
Device type: Microspheres Radionuclide (NAW)
Device problem as coded: Fluid/Blood Leak; Radiation Leak; Connection Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- TheraSphere Administration Set-CEA-1Malfunction
2124215-2026-54420 · Received Oct 13, 2026 · Event dated Sep 15, 2026
Device type: Microspheres Radionuclide (NAW)
Device problem as coded: Connection Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- TheraSphere Administration Set, REF OTT-SPE-FP-226 (990226.SPE)Open, Classified
Z-2327-2021 · Started Jul 23, 2021 · Posted by FDA Aug 19, 2021
Reason given: Potential for leaks and loosening at the patient catheter connection
Cause as FDA categorized it: Component change control · Device type: Microspheres Radionuclide (NAW)
- TheraSphere Administration Set, REF OTT-SPE-FP-001 (990264.SPE)Open, Classified
Z-2328-2021 · Started Jul 23, 2021 · Posted by FDA Aug 19, 2021
Reason given: Potential for leaks and loosening at the patient catheter connection
Cause as FDA categorized it: Component change control · Device type: Microspheres Radionuclide (NAW)
Published research
The most relevant PubMed records for "TheraSphere"[tiab]. The summary above synthesizes these.
- The cost-effectiveness of TheraSphere in patients with hepatocellular carcinoma who are eligible for transarterial embolization.
Manas D, Bell JK, Mealing S, et al. · Eur J Surg Oncol · 2021Research Support, Non-U.S. Gov't
- New Kids on the Block.
Karamchandani DM, Hammad H, Chetty R, et al. · Arch Pathol Lab Med · 2021
- EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.
Weber M, Lam M, Chiesa C, et al. · Eur J Nucl Med Mol Imaging · 2022Practice Guideline
- Radioembolization of hepatocellular carcinoma.
Van de Wiele C · Curr Drug Discov Technol · 2010Comparative Study, Review
- Radioembolization for hepatocellular carcinoma using TheraSphere®.
Ali SM · Saudi J Gastroenterol · 2011
- Transarterial Radioembolization (TARE) Agents beyond 90Y-Microspheres.
Bouvry C, Palard X, Edeline J, et al. · Biomed Res Int · 2018Review
- Use of Yttrium-90 TheraSphere for the treatment of unresectable hepatocellular carcinoma.
Liu MD, Uaje MB, Al-Ghazi MS, et al. · Am Surg · 2004
- 90Y-TheraSpheres: The New Look of Yttrium-90.
Arnold CA, Pezhouh MK, Lam-Himlin D, et al. · Am J Surg Pathol · 2019Comparative Study, Multicenter Study
- Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group.
Salem R, Padia SA, Lam M, et al. · Eur J Nucl Med Mol Imaging · 2023
- Outcomes of Therasphere Radioembolization for Colorectal Metastases.
Abbott AM, Kim R, Hoffe SE, et al. · Clin Colorectal Cancer · 2015
- TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial.
Chauhan N, Mulcahy MF, Salem R, et al. · JMIR Res Protoc · 2019
- Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial.
Chauhan N, Bukovcan J, Boucher E, et al. · JMIR Res Protoc · 2018
Other devices of this type
Also filed under product code NAW.
- SIR-Spheres microspheresSirtex Medical, Inc. · PMA 2017
- SIR-Spheres Y-90 resin microspheresSirtex Medical, Inc. · PMA 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.